CN1611260A - Combined medicine of adefovir dipivoxil - Google Patents
Combined medicine of adefovir dipivoxil Download PDFInfo
- Publication number
- CN1611260A CN1611260A CN 200310103935 CN200310103935A CN1611260A CN 1611260 A CN1611260 A CN 1611260A CN 200310103935 CN200310103935 CN 200310103935 CN 200310103935 A CN200310103935 A CN 200310103935A CN 1611260 A CN1611260 A CN 1611260A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- medicine
- inosine
- extract
- adefovir ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 21
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 title description 6
- 229960003205 adefovir dipivoxil Drugs 0.000 title description 3
- -1 mannopeptide Chemical compound 0.000 claims abstract description 18
- 239000000284 extract Substances 0.000 claims abstract description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 6
- 108010046075 Thymosin Proteins 0.000 claims abstract description 6
- 102000007501 Thymosin Human genes 0.000 claims abstract description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 6
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims abstract description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 3
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 claims abstract description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 3
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims abstract description 3
- 229930010555 Inosine Natural products 0.000 claims abstract description 3
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 3
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229950002441 glucurolactone Drugs 0.000 claims abstract description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 3
- 229960003786 inosine Drugs 0.000 claims abstract description 3
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 claims abstract description 3
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims abstract description 3
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 3
- 239000011734 sodium Substances 0.000 claims abstract description 3
- 229960003080 taurine Drugs 0.000 claims abstract description 3
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 3
- 239000011718 vitamin C Substances 0.000 claims abstract description 3
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 3
- 229940046009 vitamin E Drugs 0.000 claims abstract description 3
- 239000011709 vitamin E Substances 0.000 claims abstract description 3
- 229960001997 adefovir Drugs 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 7
- 239000009636 Huang Qi Substances 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 239000002131 composite material Substances 0.000 claims description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 2
- GRSZFWQUAKGDAV-KQYNXXCUSA-L IMP(2-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-L 0.000 claims description 2
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 claims description 2
- 108010058907 Tiopronin Proteins 0.000 claims description 2
- 229960001456 adenosine triphosphate Drugs 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- SPPIIOPGDLITJE-VLQRKCJKSA-N diazanium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihy Chemical compound N.N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SPPIIOPGDLITJE-VLQRKCJKSA-N 0.000 claims description 2
- 235000003969 glutathione Nutrition 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 108010010998 polyactin A Proteins 0.000 claims description 2
- 229960004245 silymarin Drugs 0.000 claims description 2
- 235000017700 silymarin Nutrition 0.000 claims description 2
- 229960004402 tiopronin Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 abstract description 4
- 210000004185 liver Anatomy 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 4
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 108010024636 Glutathione Proteins 0.000 abstract 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- 229940047169 astragalus root extract Drugs 0.000 abstract 1
- 235000021028 berry Nutrition 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 235000013902 inosinic acid Nutrition 0.000 abstract 1
- 210000005229 liver cell Anatomy 0.000 abstract 1
- 229950000628 silibinin Drugs 0.000 abstract 1
- 235000014899 silybin Nutrition 0.000 abstract 1
- 235000011178 triphosphate Nutrition 0.000 abstract 1
- 239000001226 triphosphate Substances 0.000 abstract 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 7
- 208000002672 hepatitis B Diseases 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 5
- 229960001627 lamivudine Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a medicine composition containing Adphuweizhi and one kind or several kinds of the following medicine of thymosin, mannopeptide, inosine, sodium inosine monophosphate, astragalus root extract, flavescent sophora root extract, salvia root extract, schisandra berry extrat,silibinin, silibinin-N-methylglucamine, bifendate, taurine, diammonium glycyrrhatinate, reduced glutathione, tripronin, vitamin C, vitamin E, glucurolactone and adernosine triphosphate. Said invented medicine composition not only has the action of resisting HBV virus, but also has the good action of protecting liver cell and preventing and curing fibrosis of liver.
Description
Technical field the invention belongs to medical technical field, relates to a kind of composite reagent thing for the treatment of hepatitis B.
The background technology whole world according to estimates has 3.5 hundred million people to infect hepatitis B virus for a long time approximately, wherein 75% lives in the Asian-Pacific area, and these philtrums have at least 1/4th will finally become hepatitis B chronic infection and complication thereof, and as liver cirrhosis, liver function is lost compensatory and hepatocarcinoma.
Still there be not specific medicament aspect the treatment hepatitis B at present, most popular in the anti-hepatic-B virus medicine is lamivudine, it belongs to the ucleosides antiviral agents, the inhibitory action stronger to duplicating of hepatitis b virus hbv, though lamivudine curative effect aspect the treatment chronic viral hepatitis B is better, but the patient uses for a long time and can produce the variation of HBV pol gene, and use the course of treatment long more, the variation incidence rate is high more, thereby generation drug resistance, make the state of an illness repeatedly, aggravate and quickened the generation of hepatic fibrosis, even finally cause liver cirrhosis and hepatocarcinoma.
Chinese invention patent application number 99813268.3 discloses a kind of adefovir ester and lamivudine group combination with medication technology, be used for preventing to produce virus variation in anti-HBV process, because adefovir ester itself has very strong anti-HBV effect and is difficult for causing virus variation, clinical research shows that it not only has significant inhibitory effect to hepatitis virus, and wild type and lamivudine Drug resistance HBV Strain all had significant therapeutic effect, so being combined in of adefovir ester and lamivudine has the repetition part on the efficacy of drugs.
The summary of the invention adefovir ester is the new ucleosides antiviral agents of synthetic, chemical name is: 9-[2-(the two methoxy acetyl of two pivaloyl oxygen methyl acid phosphates) adenine], molecular formula C20H32N5O8P, molecular weight 501.48 is called adefovir ester, adefovir ester, adefovir dipivoxil etc. usually again.Adefovir ester tyrosine phosphorylation in cell is formed with active adefovirdipivoxil diphosphate, this active metabolite can competitiveness penetrate in the viral DNA chain, suppress the HBV-DNA polymerase, thereby blocking virus DNA's is synthetic, suppress virus replication, it does not disturb the metabolism of normal cell deoxynucleoside, and DNA in mammalian cells content is not almost had influence.
The subject matter that the treatment viral hepatitis B will face is not only and is wanted anti-hepatitis virus and prevent chemical sproof generation; and top priority is a liver protecting; repair hepar damnification and recover liver function, because guarantee that the normal operation of liver function is a prerequisite of keeping normal activities.The purpose of this invention is to provide a kind of combination medicine (compound preparation) for the treatment of chronic viral hepatitis B; this medicine not only has efficiently antivirus action rapidly; impel HBVDNA to turn out cloudy fast; and protect hepatocyte in addition and repair hepar damnification and the effect of recovery liver function, have the excellent drug synergism with adefovir ester.
In order to achieve the above object, the present invention adopts one or more combinations in adefovir ester and the following medicine: thymosin, mannatide, inosine, sodium inosine-5-monophosphate, Radix Astragali extract, Radix Sophorae Flavescentis extract, Radix Salviae Miltiorrhizae extract, Fructus Schisandrae Chinensis extrat, silymarin, silybin-N-methylglucamine, bifendate, taurine, diammonium glycyrrhizinate, reduced glutathion, tiopronin, vitamin C, vitamin E, glucurolactone, adenosine triphosphate.
Above-mentioned 19 kinds of medicines all have the certain protection effect to liver, have can human body immunity improving power, what have has protecting the liver, detoxifies, falls the effect of enzyme and antagonism body free radical, what have has an effect that improves the organism metabolism function.One or more of above-mentioned 19 kinds of medicines are combined into compound preparation with the adefovir ester with efficient resisting HBV virus, and treatment hepatitis B diseases aspect is had good drug synergism.
Adefovir ester comprises acceptable medicinal derivative on the medicine, trim and various crystalline structure.
Sign in the needs of pharmaceutical dosage form and production use, can rationally add proper quantity of medicinal auxiliary material in pharmaceutical formulation, pharmaceutical dosage form comprises tablet, capsule, oral liquid, granule, injection.
The specific embodiment
Embodiment one: the composition of medicine of adefovir ester and thymosin
Get A Defuwei ester amorphous solid powder, thymosin and an amount of medicinal material of catching, adopt tablet producing technology to be made into the enteric solubility tablet, make every to contain 10 milligrams of adefovir esters, 5 milligrams of thymosins.
Embodiment two: the composition of medicine of the adefovir ester and the Radix Astragali, Radix Sophorae Flavescentis extract
Get A Defuwei ester amorphous solid powder, Radix Astragali extract, Radix Sophorae Flavescentis extract and an amount of medicinal material of catching, adopt tablet producing technology to be made into tablet, make every to contain 10 milligrams of adefovir esters, 50 milligrams of Radix Astragali total saponins, 240 milligrams of total oxymatrines.
Claims (3)
1. one or more combinations in adefovir ester and the following medicine: thymosin, mannatide, inosine, sodium inosine-5-monophosphate, Radix Astragali extract, Radix Sophorae Flavescentis extract, Radix Salviae Miltiorrhizae extract, Fructus Schisandrae Chinensis extrat, silymarin, silybin-N-methylglucamine, bifendate, taurine, diammonium glycyrrhizinate, reduced glutathion, tiopronin, vitamin C, vitamin E, glucurolactone, adenosine triphosphate.
2. composite reagent thing according to claim 1, but it is characterized in that acceptable medicinal derivative, trim or various crystalline structure on the adefovir ester drug of choice thing.
3. according to claim 1,2 described composite reagent things, it is characterized in that to add pharmaceutic adjuvant as required, medicine is made tablet, capsule, oral liquid, granule, injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310103935 CN1611260A (en) | 2003-11-01 | 2003-11-01 | Combined medicine of adefovir dipivoxil |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310103935 CN1611260A (en) | 2003-11-01 | 2003-11-01 | Combined medicine of adefovir dipivoxil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1611260A true CN1611260A (en) | 2005-05-04 |
Family
ID=34756860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310103935 Pending CN1611260A (en) | 2003-11-01 | 2003-11-01 | Combined medicine of adefovir dipivoxil |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1611260A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007065314A1 (en) * | 2005-12-08 | 2007-06-14 | Pficker Pharmaceuticals, Ltd. | Compound preparation for treating virus hepatopathy |
| CN100353981C (en) * | 2006-07-06 | 2007-12-12 | 汪甬伟 | Medicine for auxiliary treating hepatitis |
| CN1985987B (en) * | 2005-12-19 | 2010-05-12 | 山东轩竹医药科技有限公司 | Medicine composition of glycyrrhizic acid or its salt and reduced glutathione |
| CN102266562A (en) * | 2010-06-04 | 2011-12-07 | 北京阜康仁生物制药科技有限公司 | Medicine composition for treating viral hepatitis |
| CN103550242A (en) * | 2013-11-22 | 2014-02-05 | 四川国康药业有限公司 | Pharmaceutical composition for treating hepatic fibrosis and preparation method thereof |
| CN104758827A (en) * | 2015-03-26 | 2015-07-08 | 程厚华 | Combination drug for treating acute viral hepatitis |
| CN104998250A (en) * | 2015-07-29 | 2015-10-28 | 福建广生堂药业股份有限公司 | Entecavir and mannatide drug composition and preparation method thereof |
-
2003
- 2003-11-01 CN CN 200310103935 patent/CN1611260A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007065314A1 (en) * | 2005-12-08 | 2007-06-14 | Pficker Pharmaceuticals, Ltd. | Compound preparation for treating virus hepatopathy |
| CN1895671B (en) * | 2005-12-08 | 2012-11-28 | 淮北辉克药业有限公司 | Compound preparation for treating viral liver disease |
| CN1985987B (en) * | 2005-12-19 | 2010-05-12 | 山东轩竹医药科技有限公司 | Medicine composition of glycyrrhizic acid or its salt and reduced glutathione |
| CN100353981C (en) * | 2006-07-06 | 2007-12-12 | 汪甬伟 | Medicine for auxiliary treating hepatitis |
| CN102266562A (en) * | 2010-06-04 | 2011-12-07 | 北京阜康仁生物制药科技有限公司 | Medicine composition for treating viral hepatitis |
| CN103550242A (en) * | 2013-11-22 | 2014-02-05 | 四川国康药业有限公司 | Pharmaceutical composition for treating hepatic fibrosis and preparation method thereof |
| CN103550242B (en) * | 2013-11-22 | 2015-07-15 | 四川国康药业有限公司 | Pharmaceutical composition for treating hepatic fibrosis and preparation method thereof |
| CN104758827A (en) * | 2015-03-26 | 2015-07-08 | 程厚华 | Combination drug for treating acute viral hepatitis |
| CN104758827B (en) * | 2015-03-26 | 2018-06-19 | 程厚华 | A kind of composition of medicine for being used to treat acute viral hepatitis |
| CN104998250A (en) * | 2015-07-29 | 2015-10-28 | 福建广生堂药业股份有限公司 | Entecavir and mannatide drug composition and preparation method thereof |
| CN104998250B (en) * | 2015-07-29 | 2018-05-29 | 福建广生堂药业股份有限公司 | A kind of Entecavir and mannosan peptide medicine composite and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1611260A (en) | Combined medicine of adefovir dipivoxil | |
| CN109364074A (en) | 6-aminonicotinamide is preparing the purposes in therapeutic agent for hepatitis B as effective component | |
| CN102631384A (en) | Application of pomegranate in preparing medicament for treating or preventing hepatitis B virus infection | |
| CN101721455B (en) | Manyflower tickclove herb extract, and preparation method and application thereof | |
| CN102813855B (en) | Chinese herbal preparation used for treating chronic viral hepatitis type b and taking method thereof | |
| CN1229124C (en) | Medicine for treating fatty liver | |
| CN101879195A (en) | Process for preparing general flavone extract of effective part of hypericum ascyron linne and new medicament appliaciton | |
| CN101406675A (en) | Medicine for treating hepatitis B | |
| CN100415232C (en) | Medicine composition for treating viral hepatitis and its preparing method | |
| CN101317868B (en) | Application of marsdenia tenacissima total saponin in preparing medicament for treating hepatitis B | |
| CN1698775A (en) | Pharmaceutical composition containing lamivudine | |
| CN101099850B (en) | Medicine composition for treating chronic active hepatitis and early-stage hepatocirrhosis and preparation method thereof | |
| CN102100775B (en) | Anti-hepatitis-virus medicament composition as well as preparation method and application thereof | |
| CN103690552A (en) | Pharmaceutical composition and application thereof to preparing pharmaceutical preparation for treating hepatitis B | |
| CN102008588B (en) | Medicine composition for curing hepatic encephalopathy and hepatitis B | |
| CN100591349C (en) | Chinese medicine for treating AIDS | |
| CN101401847A (en) | Medicament composition containing lamivudine | |
| CN105687220A (en) | Novel medicine composition for treating viral hepatitis B | |
| CN1330373C (en) | Medicine composition containing alfa-interferon , adefovir and FTC | |
| CN1190221C (en) | Medicine for curing hepatitis B | |
| CN101385763A (en) | Use of snow ganoderma lucidum total saponin in preparing antiviral property hepatitis medicine | |
| CN1238053C (en) | Medicine composition containing alfa-interferon , lamivudine and adefovir | |
| CN101167779B (en) | Application of Lagotis glauca gaertn extract in preparing antiviral medicine | |
| CN1242768C (en) | Hepatitis treating medicine and its preparing process | |
| CN101057906B (en) | Traditional Chinese medicinal composition for treating hepatitis and its pharmaceutical preparation and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20060908 Address after: 32F, global Plaza, No. 54, 158, Fuzhou Applicant after: Guangshengtang pharmaceutical Industry Co., Ltd. Fujian Address before: Room 1, unit 10, building 36, No. two, 404 Road, Qingdao, Shandong, Anshan Applicant before: Yang Xihong |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |